Official ESCRS | European Society of Cataract & Refractive Surgeons
Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance

Take a look inside the London 2014 Congress


Then register to join us
in Barcelona!

Triamcinolone acetonide as an adjunct to Bevacizumab for prevention of corneal neovascularization

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Session Details

Session Title: Cornea - Medical

Session Date/Time: Monday 07/09/2015 | 08:00-10:30

Paper Time: 08:00

Venue: Room 17

First Author: : H.Zare Mehrjardi IRAN

Co Author(s): :    R. Ghaffari   M. Mahbod   H. Hashemi              

Abstract Details


To evaluate the short-term effects of a single subconjunctival injection of triamcinolone acetonide as an adjunct to subconjunctival bevacizumab for prevention of corneal neovascularization in rats.


Experimental study; Farabi Eye Hospital, Tehran, Iran.


Chemical cauterization was performed in the central cornea of the right eye in 48 male Sprague Dawley rats. Immediately after the injury, the rats were randomly assigned to four treatment groups: controls (n=10), received subconjunctival injection of 0.02 mL balanced salt solution group 1 (n=12), received 0.02 mL bevacizumab (25 mg/mL) group 2 (n=11), were treated with 0.02 mL triamcinolone acetonide (40 mg/mL) and group 3 (n=11), received both bevacizumab and triamcinolone acetonide. On days 7 and 14 after cauterization, digital photographs of the corneas were taken and the area of neovascularization was calculated and compared among the study groups.


The area of corneal neovascularization in all three treatment groups was less than the controls (P<0.05 for all comparisons). On day 7, the corneal avascular area was largest in group 3 (63%). On day 14, the area of corneal neovascularization in groups 2 and 3 was smaller than that in group 1 (P=0.031 and 0.011, respectively), but the difference between groups 2 and 3 was not statistically significant (P=0.552). Microscopic evaluation of the cornea was compatible with gross findings; inflammation and the number of new vessels was the least in group 3.


Triamcinolone acetonide was more effective than bevacizumab in inhibiting corneal neovascularization. Its adjunctive administration to bevacizumab resulted in even better prevention of corneal neovascularization. However, the produced combined effect was less than the sum of their separate effects and did not match additive or synergistic interactions.

Financial Interest:


Back to previous